Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses - Immunologie intégrative des tumeurs et immunothérapie des cancers
Article Dans Une Revue OncoImmunology Année : 2017

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

Résumé

Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8+ T cells (CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted considerable interest in the cancer therapy field. In the current study, we have exploited the unique ability of NKT cells to serve as T-helper cells to license dendritic cells (DCs) for cross priming with the aim to generate efficient CTL antitumor responses. To this end, we designed a nanoparticle-based vaccine to target cross-priming DCs via the Clec9a endocytic pathway. Our results showed for the first time that simultaneous co-delivery of the NKT agonist α-galactosylceramide and tumor self-antigens (Trp2 and gp100) to CD8α+ DCs promotes strong antitumor responses in prophylactic and therapeutic settings (advanced solid tumor model in the mouse). We attributed the vaccine's therapeutic effects to NKT cells (but not to T-helper lymphocytes) and CD8+ T cells. Efficacy was correlated with an elevated ratio between tumor antigen-specific CD8+ T cells and regulatory CD4+ T lymphocytes within the tumor. The nanoparticle-based vaccine actively targeted human CLEC9A-expressing BDCA3+ DCs - the equivalent of murine cross-priming CD8α+ DCs - and induced a strong expansion of effector memory tumor self-antigen (Melan -A)-specific CD8+ T cells from peripheral blood mononuclear cells sourced from healthy donors and melanoma patients. Together, our result shed light on novel therapeutic approaches for controlling tumor development.

Domaines

Vaccinologie
Fichier principal
Vignette du fichier
Co-delivery of the NKT agonist -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes.pdf (1.87 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04276618 , version 1 (30-08-2024)

Identifiants

Citer

Reem Ghinnagow, Julie de Meester, Luis Javier Cruz, Caroline Aspord, Stéphanie Corgnac, et al.. Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. OncoImmunology, 2017, 6 (9), pp.e1339855. ⟨10.1080/2162402X.2017.1339855⟩. ⟨hal-04276618⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

More